



All

Images

Videos

翻译成中文

关闭取词

35,500 Results

Any time ▾

Second-line treatment in advanced pancreatic cancer: a ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718508>

introduction. **Pancreatic cancer** has an estimated 5-year survival rate of 5%–6% and the majority of **patients** present with unresectable disease [1, 2]. For the past 10–15 years, gemcitabine has been considered the front-line **chemotherapy** in both locally **advanced** and metastatic disease due to its positive effect on quality of life and—to a lesser extent—overall survival [].

Cited by: 111

Author: O. E. Rahma, A. Duffy, D. J. Liewehr, S. ...

Publish Year: 2013

Second-Line Therapy for Gemcitabine-Refractory Pancreatic ...

<https://www.cancernetwork.com/gastrointestinal-cancer/second-line-therapy-gemcitabine...> ▾

Sep 02, 2008 · In an Italian/Swiss multicenter retrospective survey,[41] multivariate analysis in 160 **gemcitabine-resistant pancreatic cancer patients** revealed that performance status at the beginning of **second-line therapy** and response to **first-line treatment** are important determinants of survival in **second-line chemotherapy**.

Cited by: 16

Author: Khaldoun Almhanna, Richard Kim

Publish Year: 2008

Second-Line Therapy for Gemcitabine-Refractory Pancreatic ...

<https://www.cancernetwork.com/gastrointestinal-cancer/second-line-therapy-gemcitabine...> ▾

Sep 02, 2008 · Benefit from second-line **treatment** vs best supportive care alone was suggested in a preliminary report of a randomized phase II trial in which 46 (out of a planned 165) **patients with** gemcitabine-refractory **pancreatic cancer** were randomized to best supportive care with or without **chemotherapy** (5-FU, leucovorin, and oxaliplatin [Eloxatin ...

Cited by: 16

Author: Khaldoun Almhanna, Richard Kim

Publish Year: 2008

Beyond first-line chemotherapy for advanced pancreatic ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942828>

Mar 07, 2014 · Gemcitabine and **cisplatin** combined with **regional hyperthermia** as second-line treatment in patients with gemcitabine-refractory advanced **pancreatic cancer**. Int J Hyperthermia...

Cited by: 31

Author: Evan J Walker, Andrew H Ko

Publish Year: 2014

Second Line Chemotherapy for Pancreatic Cancer | Request ...

https://www.researchgate.net/.../51076122_Second_Line_Chemotherapy_for_Pancreatic_Cancer

We reviewed the clinical trials of second line chemotherapy for gemcitabine refractory **pancreatic cancer** and tried to show currently available **treatment** options.

Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer

Se Jun Park, Hyunho Kim, Kabsoo Shin, MyungAh Lee, Tae Ho Hong

Abstract

BACKGROUND

There is no standard therapy for second-line treatment of gemcitabine-refractory pancreatic cancer patients with poor performance status. A combination of chemotherapy drugs 5-fluorouracil (5-FU), leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or 5-fluorouracil/leucovorin plus nanoliposomal irinotecan can be considered as second-line treatment for such patients; however, due to toxicity, none of the regimens are recommended for patients with poor performance. Capecitabine or S-1 has relatively low toxicity and can be considered a treatment option for gemcitabine-refractory pancreatic cancer.

AIM

To investigate the efficacy and toxicity of oral chemotherapy as second-line treatment

Match Overview

1	Crossref 42 words Kohei Shitara, Akira Sawaki, Keitaro Matsuo, Chihiro Kondo et al. "A retrospective comparison of S-1 plus cisplatin for second-line treatment of gemcitabine-refractory advanced pancreatic cancer"	1%
2	Internet 24 words crawled on 22-Jul-2019 cslide.ctimeetingtech.com	1%
3	Internet 20 words crawled on 06-Mar-2017 clincancerres.aacrjournals.org	1%
4	Internet 18 words crawled on 30-Nov-2016 f1000.com	<1%
5	Internet 17 words crawled on 25-Aug-2016 www.diagnosticsimaging.com	<1%
6	Internet 15 words crawled on 29-Mar-2019 academic.oup.com	<1%
7	Crossref 14 words Germano, Domenico. "Systemic therapy of hepatocellular carcinoma: Current status and future perspectives", World Journal of Gastroenterology	<1%
8	Crossref 14 words Kentaro Sudo, Taketo Yamaguchi, Kazuyoshi Nakamura, Tadamichi Denda, Taro Hara, Takeshi Ishihara, Osamu Kamegishi et al. "Efficacy and safety of S-1 plus irinotecan in patients with gemcitabine-refractory advanced pancreatic cancer: A phase II trial"	<1%
9	Crossref 14 words T Ioka, Y Komatsu, N Mizuno, A Tsuji et al. "Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer"	<1%
10	Internet 14 words crawled on 14-Aug-2019 www.nejm.org	<1%

Oral chemotherapy for second-line treatment in patients with gemcitabine-refract



All

Images

Videos

翻译成中文

关闭取词

39,800 Results

Any time ▾

Second-line chemotherapy with S-1 was tolerated with acceptable toxicity and resulted in a relatively high disease control rate in **patients** with **gemcitabine**-resistant **advanced pancreatic cancer**. As an **oral** agent, S-1 may be a feasible **treatment** option for this **patient** population.

Phase II study of S-1 in patients with gemcitabine ...

link.springer.com/article/10.1007%2Fs00280-010-1311-3

Is this answer helpful?

Oral chemotherapy as second-line treatment option for ...

https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.4_suppl.405

We evaluated the efficacy, toxicity, and median dose intensity of **oral chemotherapy**, capecitabine, or TS-1 in **gemcitabine-refractory advanced pancreatic cancer** for **second-line treatment**. Methods: **Patients** who have progressive disease after **first-line gemcitabine-based chemotherapy** were retrospectively analyzed between Jan. 2011 and Nov. 2017. These **patients** were **treated** with capecitabine or TS-1 as **second-line treatment**.

Author: Se Jun Park, Myung Ah Lee Publish Year: 2019

Second-Line Therapy for Gemcitabine-Refractory Pancreatic ...

<https://www.cancernetwork.com/gastrointestinal-cancer/second-line-therapy-gemcitabine...>

Sep 02, 2008 - Benefit from **second-line treatment** vs best supportive care alone was suggested in a preliminary report of a randomized phase II trial in which 46 (out of a planned 165) **patients with gemcitabine-refractory pancreatic cancer** were randomized to best supportive care with or without chemotherapy (5-FU, leucovorin, and oxaliplatin [Eloxatin] combination).[7]

Cited by: 18 Author: Khaldoun Almhanna, Richard Kim

Publish Year: 2008

Second-Line Therapy for Gemcitabine-Refractory Pancreatic ...

<https://www.cancernetwork.com/gastrointestinal-cancer/second-line-therapy-gemcitabine>